Stephens Inc’s Haemonetics HAE Stock Holding History

Stephens Inc’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-17,307	Closed	-$683K	–	770
2017 Q2	$683K	Buy	+17,307	New	+$711K	0.02%	506

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Stephens Inc's HAE Position: Q3 2017 in Review

Stephens Inc sold out of Haemonetics (HAE) in Q3 2017, closing a stake of 17,307 shares — an estimated $683K sold.

Stephens Inc first reported a position in HAE in Q2 2017 and held it in 1 quarter. The position peaked at $683K in Q2 2017. 207 funds tracked by Wall St. Rank hold HAE as of Q3 2017.

Stephens Inc reported no remaining Haemonetics position as of Q3 2017 after selling out during the quarter.
Stephens Inc sold 17,307 Haemonetics shares in Q3 2017, an estimated $683K.
Stephens Inc first reported a position in Haemonetics in Q2 2017 and held it in 1 quarter.
Stephens Inc's Haemonetics position peaked at $683K in Q2 2017.
207 funds tracked by Wall St. Rank held Haemonetics as of Q3 2017.

Based on Stephens Inc's 13F filing for Q3 2017, filed 8 Nov 2017.